McNeil loratadine
This article was originally published in The Tan Sheet
Executive Summary
J&J division will market OTC equivalent to Schering-Plough's Claritin under the brand name Proclir. On July 19, FDA deemed McNeil's NDA (021339) for loratadine tablets "approvable." Wyeth's NDA (021375) for Alavert, the equivalent to Claritin Reditabs, was pronounced "approvable" on July 3 (1"The Tan Sheet" July 22, 2002, In Brief). Schering filed patent infringement lawsuits against McNeil in December, Wyeth in January...
You may also be interested in...
Wyeth OTC loratadine “approvable”
FDA deems firm's application for Alavert, an OTC version of Schering-Plough's Claritin Reditabs (loratadine), approvable July 3. Alavert will employ CIMA Labs' DuraSolv technology; CIMA announced an exclusive license, supply agreement with Wyeth June 27 ("1The Tan Sheet" July 1, 2002, p. 4). Wyeth filed an NDA under section 505(b)(2) in January; McNeil also filed a 505(b)(2) application in November. Schering sued both companies for patent infringement 2("The Tan Sheet" Feb. 4, 2002, p. 3)...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.